60510 Federal Register / Vol. 76, No. 189 / Thursday, September 29, 2011 / Notices 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; ‘‘Combined Multipurpose 

Prevention Strategies for Sexual and 

Reproductive Health’’. 

Date: October 18, 2011. 

Time: 12:30 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6700B 

Rockledge Drive, Bethesda, MD 20817 

(Telephone Conference Call). 

Contact Person: Jane K. Battles, PhD, 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institutes of Health/NIAID, 6700B 

Rockledge Drive, Room 3147, Bethesda, MD 

20892–7616, 301–451–2744, 

battlesja@mail.nih.gov. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; ‘‘Combined Multipurpose 

Prevention Strategies for Sexual and 

Reproductive Health’’. 

Date: October 31, 2011. 

Time: 9 a.m. to 12 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6700B 

Rockledge Drive, Bethesda, MD 20817 

(Telephone Conference Call). 

Contact Person: Jane K. Battles, PhD, 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institutes of Health/NIAID, 6700B 

Rockledge Drive, Room 3147, Bethesda, MD 

20892–7616, 301–451–2744, 

battlesja@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: September 23, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–25096 Filed 9–28–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: Compositions and Method for 

Preventing Reactogenicity Associated 

with Administration of Immunogenic 

Live Rotavirus Compositions 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

404.7(a)(1)(i), that the National 

Institutes of Health, Department of 

Health and Human Services, is 

contemplating the grant of an exclusive 

patent license to practice the inventions 

embodied in U.S. Provisional Patent 

Application No. 60/178,689, filed 

January 28, 2000 [HHS Ref. No. E–088– 

2000/0–US–01], now expired; PCT 

Patent Application No. PCT/US01/ 

02686 [HHS Ref. No. E–088–2000/0– 

PCT–02] filed January 26, 2001, which 

published as WO/2001/54718 on August 

2, 2001, now expired; U.S. Patent No. 

7,431,931 [HHS Ref. No. E–088–2000/0– 

US–06]; Australian Patent No. 784344 

[HHS Ref. No. E–088–2000/0–AU–04]; 

German Patent No. 60141681.308 [HHS 

Ref. No. E–088–2000/0–DE–08]; French 

Patent No. 1251869 [HHS Ref. No. E– 

088–2000/0–FR–09]; United Kingdom 

Patent No. 1251869 [HHS Ref. No. E– 

088–2000/0–GB–10]; and Canadian 

Patent Application No. 2398428 [HHS 

Ref. No. E–088–2000/0–CA–05], entitled 

‘‘Compositions and Method for 

Preventing Reactogenicity Associated 

with Administration of Immunogenic 

Live Rotavirus Compositions,’’ and all 

continuing applications to International 

Medica Foundation, having a place of 

business in Rochester, Minnesota. The 

patent rights in these inventions have 

been assigned to the United States of 

America. 

The prospective exclusive license 

territory may be ‘‘worldwide’’, and the 

field of use may be limited to ‘‘rhesusbased rotavirus therapeutic and/or 

prophylactic vaccines.’’ 

DATES: Only written comments and/or 

applications for a license which are 

received by the NIH Office of 

Technology Transfer on or before 

October 31, 2011 will be considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, comments, 

and other materials relating to the 

contemplated exclusive license should 

be directed to: Kevin W. Chang, Ph.D., 

Senior Licensing and Patenting 

Manager, Office of Technology Transfer, 

National Institutes of Health, 6011 

Executive Boulevard, Suite 325, 

Rockville, MD 20852–3804; Telephone: 

(301) 435–5018; Facsimile: (301) 402– 

0220; E-mail: changke@mail.nih.gov. 

SUPPLEMENTARY INFORMATION: The 

present invention provides 

compositions for making a medicament 

and methods for the administration of 

vaccine compositions for protection 

against human rotaviral disease without 

significant reactogenicity. Human x 

rhesus reassortant rotavirus 

compositions were made which when 

administered during the first 7 to about 

10 days of life, provided a composition 

which was non-reactogenic followed by 

booster immunizations at 16 to 18 

weeks or 14 to 20 weeks, up to 1 year 

of age. The immune response induced 

by the initial neonatal administration of 

the live rotavirus vaccine composition 

protects the infant from the 

reactogenicity of the composition when 

administered as a second vaccine dose 

at or after 2 months of age. 

Administration of the immunogenic 

composition also is expected to ablate or 

significantly diminish the increase in 

the excess of intussusception observed 3 

to 7 days following administration of 

the initial dose of rotavirus vaccine at 

about 2 to 4 months. 

The prospective exclusive license will 

be royalty bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR 404.7. The prospective 

exclusive license may be granted unless 

within thirty (30) days from the date of 

this published notice, the NIH receives 

written evidence and argument that 

establishes that the grant of the license 

would not be consistent with the 

requirements of 35 U.S.C. 209 and 37 

CFR 404.7. 

Applications for a license in the field 

of use filed in response to this notice 

will be treated as objections to the grant 

of the contemplated exclusive license. 

Comments and objections submitted to 

this notice will not be made available 

for public inspection and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: September 22, 2011. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 2011–25098 Filed 9–28–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Office of the Secretary 

[Docket No. DHS–2011–0076] 

DHS Data Privacy and Integrity 

Advisory Committee; Meeting 

AGENCY: Privacy Office, DHS. 

ACTION: Notice. 

SUMMARY: On Wednesday, September 

21, 2011, the DHS Privacy Office 

announced in the Federal Register at 76 

FR 58524 that the Data Privacy and 


tkelley on DSKG8SOYB1PROD with NOTICES
Federal Register / Vol. 76, No. 189 / Thursday, September 29, 2011 / Notices 60511 

Integrity Advisory Committee would 

meet on October 5, 2011, in Arlington, 

Virginia. This notice supplements that 

original meeting notice. 

DATES: The DHS Data Privacy and 

Integrity Advisory Committee will meet 

on Wednesday, October 5, 2011, from 1 

p.m. to 5 p.m. Please note that the 

meeting may end early if the Committee 

has completed its business. 

SUPPLEMENTARY INFORMATION: Notice of 

this meeting is given under the Federal 

Advisory Committee Act, 5 U.S.C. App., 

which requires that notices of meetings 

of advisory committees be announced in 

the Federal Register 15 days prior to the 

meeting date. A notice of the meeting of 

the Board was published in the Federal 

Register on September 21, 2011, 14 days 

prior to the meeting, due to the 

mistaken delivery of the notice to 

another Federal agency rather than to 

the Federal Register. The other Federal 

agency received the notice, and the 

Federal Register office received that 

agency’s material. By the time the error 

was noted by each office and DHS was 

contacted, DHS could no longer meet 

the 15 day requirement. During the 

meeting the Committee will discuss 

draft guidance to the Department on 

privacy protections for information 

sharing within DHS. The draft guidance 

will be posted on the Committee’s web 

site (http://www.dhs.gov/privacy) in 

advance of the meeting. If you wish to 

submit comments on the draft guidance, 

you may do so in advance of the 

meeting by forwarding them to the 

Committee at the locations listed under 

ADDRESSES in the original notice. Please 

include the Docket Number (DHS 2011– 

0076) in your comments. A public 

comment period will be held during the 

meeting from 4 p.m. to 4:30 p.m., and 

speakers are requested to limit their 

comments to 3 minutes. If you would 

like to address the Committee at the 

meeting, we request that you register in 

advance by contacting Martha K. 

Landesberg at the address listed under 

ADDRESSES in the original notice or sign 

up at the registration desk on the day of 

the meeting. 

FOR FURTHER INFORMATION CONTACT: 

Martha K. Landesberg, Executive 

Director, DHS Data Privacy and Integrity 

Advisory Committee, Department of 

Homeland Security, Washington, DC 

20528, by telephone (703) 235–0780, by 

fax (703) 235–0442, or by e-mail to 

PrivacyCommittee@dhs.gov. 

Dated: September 23, 2011. 

Mary Ellen Callahan, 

Chief Privacy Officer, Department of 

Homeland Security. 

[FR Doc. 2011–25079 Filed 9–28–11; 8:45 am] 

BILLING CODE 9110–9L–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Coast Guard 

[Docket No. USCG–2011–0662] 

Amendment of Marine Safety Manual, 

Volume III 

AGENCY: Coast Guard, DHS. 

ACTION: Notice of proposed policy 

change and request for comments. 

SUMMARY: The Coast Guard is 

considering cancelling its policy 

concerning the issuance of Merchant 

Mariner Credentials endorsed as Able 

Seaman-Mobile Offshore Units. The 

policy is currently found in Chapter 16 

of the Marine Safety Manual, Volume 

III. The Coast Guard will accept 

comments from the public on whether 

to cancel the policy and on any impacts 

the cancellation may have. 

DATES: Comments and related material 

must either be submitted to our online 

docket via http://www.regulations.gov 

on or before October 31, 2011 or reach 

the Docket Management Facility by that 

date. 

ADDRESSES: You may submit comments 

identified by docket number USCG– 

2011–0662 using any one of the 

following methods: 

(1) Federal eRulemaking Portal: 

http://www.regulations.gov. 

(2) Fax: 202–493–2251. 

(3) Mail: Docket Management Facility 

(M–30), U.S. Department of 

Transportation, West Building Ground 

Floor, Room W12–140, 1200 New Jersey 

Avenue, SE., Washington, DC 20590– 

0001. 

(4) Hand delivery: Same as mail 

address above, between 9 a.m. and 

5 p.m., Monday through Friday, except 

Federal holidays. The telephone number 

is 202–366–9329. 

To avoid duplication, please use only 

one of these four methods. See the 

‘‘Public Participation and Request for 

Comments’’ portion of the 

SUPPLEMENTARY INFORMATION section 

below for instructions on submitting 

comments. 

FOR FURTHER INFORMATION CONTACT: If 

you have questions about this notice, 

call or e-mail Luke B. Harden, Mariner 

Credentialing Program Policy Division 

(CG–5434), U.S. Coast Guard, telephone 

202–372–2357, e-mail 

CG5434@uscg.mil. If you have questions 

on viewing material in the docket, call 

Renee V. Wright, Program Manager, 

Docket Operations, telephone 202–366– 

9826. 

SUPPLEMENTARY INFORMATION: 

Public Participation 

You may submit comments and 

related material regarding whether to 

cancel the Able Seaman-Mobile 

Offshore Units (AB–MOU) endorsement. 

All comments received will be posted, 

without change, to http:// 

www.regulations.gov and will include 

any personal information you have 

provided. 

Submitting comments: If you submit a 

comment, please include the docket 

number for this notice (USCG–2011– 

0662) and provide a reason for each 

suggestion or recommendation. You 

may submit your comments and 

material online or by fax, mail or hand 

delivery, but please use only one of 

these means. We recommend that you 

include your name and a mailing 

address, an e-mail address, or a 

telephone number in the body of your 

document so that we can contact you if 

we have questions regarding your 

submission. 

To submit your comment online, go to 

http://www.regulations.gov and click on 

the ‘‘submit a comment’’ box, which 

will then become highlighted in blue. In 

the ‘‘Document Type’’ drop down menu, 

select ‘‘Notices’’ and insert ‘‘USCG– 

2011–0662’’ in the ‘‘Keyword’’ box. 

Click ‘‘Search,’’ and then click on the 

balloon shape in the ‘‘Actions’’ column. 

If you submit your comments by mail or 

hand delivery, submit them in an 

unbound format, no larger than 81⁄2; by 

11 inches, suitable for copying and 

electronic filing. If you submit 

comments by mail and would like to 

know that they reached the Facility, 

please enclose a stamped, self-addressed 

postcard or envelope. 

We will consider all comments and 

material received during the comment 

period. 

Viewing the comments: To view the 

comments, go to http:// 

www.regulations.gov and click on the 

‘‘Read Comments’’ box, which will then 

become highlighted in blue. In the 

‘‘Keyword’’ box, insert ‘‘USCG–2011– 

0662’’ and click ‘‘Search.’’ Click the 

‘‘Open Docket Folder’’ in the ‘‘Actions’’ 

column. If you do not have access to the 

internet, you may view the docket 

online by visiting the Docket 

Management Facility in Room W12–140 

on the ground floor of the Department 

of Transportation West Building, 1200 

New Jersey Avenue, SE., Washington, 


tkelley on DSKG8SOYB1PROD with NOTICES